Aadi Bioscience Inc FYARRO Corporate Call Transcript
Greetings, and welcome to the Aadi Bioscience FYARRO's Approval Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Andrew Kwon, Vice President of Corporate Development at Aadi Bioscience. Thank you Andrew, you may begin.
Thank you, operator. Welcome to our conference call to discuss the FDA approval of FYARRO for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor, also known as PEComa. A press release announcing the approval is available on our website at aadibio.com.
Before we begin, I'd like to remind everyone that during this call, we will be making forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties and therefore actual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
